Sagimet Biosciences SGMT 深 滬
已收盤 06-18 16:00:00 美东时间
6.68
+0.150
+2.30%
華盛通- 最 高6.855
- 今 開6.55
- 成交量 359.25万股
- 最 低 6.55
- 昨 收 6.53
- 總市值 4.13亿
- 52周最高 11.41
- 市盈率 靜 --
- 換手率 5.82%
- 52周最低 4.50
- 委 比 -50.00%
- 總股本 6175.18万
- 歷史最高 20.71
- 量 比 4.64
- 振 幅 4.67%
- 歷史最低 1.73
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday. Shares of Legend Biotech Corp (NASDAQ:LEGN) fell sharply in pre-market trading after the company announced the pricing of public offering. Legend Biotech priced a public offering of 7.7 million ADSs at ...
06-18 20:02
Sagimet Biosciences Announces Board Changes and Director Elections
The latest update is out from Sagimet Biosciences, Inc. Class A ( ($SGMT) ). On...
06-13 05:00
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards
An announcement from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now avail...
06-04 06:07
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults
https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-associated-steatohepatitis-mash-in-adults
06-03 23:30
Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased
Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trialPhase 1 data show rapid reductions in cholesterol
05-27 19:15
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences, a clinical-stage biopharmaceutical company, announced that its management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York. A fireside chat will be held at 2pm ET, with a webcast available on Sagimet’s website and an archived replay for 90 days. Sagimet focuses on developing novel FASN inhibitors targeting metabolic and fibrotic pathways in conditions lin...
05-13 11:00
Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 41.07 percent increase over losses of $(0.56) per share
05-12 19:45
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi May 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Axsome Therapeutics and Onsemi on Tuesday. HIGHLIGHTS * Applied Materials AMA
05-05 15:07
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
